Clinical Trial · NCT05541367

Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

Overview

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor(ER)-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs , to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.

Sponsor

Tongji Hospital

Contacts

ZHU XIAOHUA, DR (PRINCIPAL_INVESTIGATOR)

ZHU XIAOHUA, DR (CONTACT)

evazhu@vip.sina.com

13971513770

ClinicalTrials.gov

NCT05541367

Drug / Compound

Fluoroestradiol

Isotope(s):
Target(s):
  • Estrogen Receptor
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Patients with pathologically confirmed breast cancer

Exclusion

  • Severe underlying diseases that cannot cooperate with PET examination